HGEN Shareholder Update: Robbins LLP Reminds Investors of Class Action Filed Against Humanigen, Inc. (HGEN)

Author's Avatar
Aug 30, 2022

The Class: Shareholder rights law firm Robbins+LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Humanigen, Inc. (NASDAQ: HGEN) securities between May 28, 2021 and July 12, 2022, for violations of the Securities Exchange Act of 1934. Humanigen is a clinical-stage biopharmaceutical company that focuses on preventing and treating an immune hyper-response called "cytokine storm," which can result in organ failure and death. The Company’s lead product candidate is proprietary antibody lenzilumab, which is under development as a treatment for, among other things, cytokine storm associated with COVID-19.